Gastric Caner
Conditions
Interventions
Group interventon:laparoscopic proximal gastrectomy with Overlap anastomosis plus Toupet
Sponsors
The Sixth Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1)Patients with clear pathological diagnosis and clinical evaluation of T1 or T2-3 stage (tumor = 4cm) located in the upper one-third of the stomach with proximal gastric adenocarcinoma (including gastric esophageal junction adenocarcinoma type II/III), without lymph node metastasis or distal perigastric lymph node metastasis (4d, 5, and 6 groups) on imaging (CT/EUS, etc.); (2)Male or female patients aged 18-75 years old; (3)No previous history of concomitant malignant tumors; (4)The heart, lung, liver, and kidney functions are basically normal, with an ECOG physical condition score of 0-1; (5)Follow up for at least 5 years after surgery or until patient death; (6) The patient's informed consent form has been signed.
Exclusion criteria
Exclusion criteria: (1)Gastric stump cancer; (2) Postoperative pathology confirmed T4 or IV stage (16LN metastasis or positive peritoneal exfoliated cells); (3) Borrmann III (tumor diameter greater than 8cm) or IV type, or tumor invasion of the middle one-third of the stomach; (4) The number of lymph node dissection is less than 16; (5) Receiving neoadjuvant chemotherapy; (6) Multiple gastric cancer (= 2 lesions); (7) Patients with R1 resection confirmed by postoperative pathology; (8) Pregnant or lactating women; (9) Emergency surgery; (10) Distant metastasis of liver, lung, bone, etc; Or supraclavicular lymph nodes, pelvic floor or ovarian species, peritoneal dissemination, etc; (11) Patients with other serious diseases, including cardiovascular, respiratory, kidney or liver diseases, hypertension and diabetes with poor control; (12) Mental disorders or illnesses; (13) Patients who have participated or are currently participating in other clinical trials within the first 4 weeks of enrollment; (14) Patients who have undergone surgery and whose impact has not yet been eliminated; (15) History of gastric or esophageal malignant tumors, including stromal tumors, sarcomas, lymphoma, carcinoids, etc; (16) Poor patient compliance or researchers considering poor patient compliance; (17) Some researchers believe that patients with other clinical and laboratory conditions should not participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidences of reflux esophagitis and anastomotic stenosis 12 months after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nutrition indicators;Operative time;number of harvested lymph nodes;R0 resection rate;intraoperative blood loss;Unplanned readmission rate within 30 days after surgery;mobidity;motality within 30-day after operation; | — |
Countries
China
Contacts
Public ContactYang zuli
The Sixth Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed